Why the study?
Do novel anti-platelet strategies reduce bleeding risk compared to current therapies while effectively preventing thrombosis?
Population
Patients receiving anti-platelet therapy for the prevention of heart attacks and stroke
Comparison
Novel anti-platelet strategies including… vs Current anti-platelet drugs
Design
Review
Authors
Loading...
Should not yet change antiplatelet prescribing; leaves open whether reversible P2Y12/PAR1/EP3 agents improve safety in trials.
Do novel anti-platelet strategies reduce bleeding risk compared to current therapies while effectively preventing thrombosis?
Novel anti-platelet agents targeting reversible P2Y12, PAR1, and EP3 receptors are being developed to overcome the bleeding risks and pharmacogenomic limitations of current therapies like aspirin and clopidogrel.
Fabre et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: